Prevalence and Clinicopathologic Characteristics of the Molecular Subtypes in Malignant Glioma: A Multi-Institutional Analysis of 941 Cases

Abstract

BackgroundGlioblastoma can be classified into four distinct molecular subtypes (Proneural, Neural, Classical and Mesenchymal), based on gene expression profiling. This study aimed to investigate the prevalence, clinicopathologic features and overall survival (OS) of the four molecular subtypes among all malignant gliomas.MethodsA total of 941 gene expression arrays with clinical data were obtained from the Rembrandt, GSE16011 and CGGA datasets. Molecular subtypes were predicted with a prediction analysis of microarray.ResultsAmong 941 malignant gliomas, 32.73% were Proneural, 15.09% Neural, 19.77% Classical and 32.41% Mesenchymal. The Proneural and Neural subtypes occurred largely in low-grade gliomas, while the Classical and Mesenchymal subtypes were more frequent in high-grade gliomas. A survival analysis showed that the Proneural subtype displayed a good prognosis, Neural had an intermediate correlation with overall survival, Mesenchymal had a worse prognosis than Neural, and Classical had the worst clinical outcome. Furthermore, oligodendrocytomas were preferentially assigned to the Proneural subtype, while the Mesenchymal subtype included a higher percentage of astrocytomas, compared with oligodendrocytomas. Additionally, nearly all classical gliomas harbored EGFR amplifications. Classical anaplastic gliomas have similar clinical outcomes as their glioblastoma counterparts and should be treated more aggressively.ConclusionsMolecular subtypes exist stably in all histological malignant gliomas subtypes. This could be an important improvement to histological diagnoses for both prognosis evaluations and clinical outcome predictions.

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes

“…Mesenchymal tumors are characterized by HOX upregulation, an important promoter of capillary morphogenesis and angiogenesis through VEGF 18,19 . Interestingly, the mesenchymal subtype of glioblastoma, a tumor which can also be divided into four unique molecular subtypes based on gene expression profling 20 , has the worst overall prognosis but appears to have an improved response to bevacuzimab 21 and is currently the subject of ongoing clinical investigation [http://clinicaltrials.gov/show/NCT01392209]. In addition, a recent study from Sandmann et al used a NanoString based gene expression molecular classifier to stratify patients treated in the phase III frontline glioblastoma AVAglio trial into established molecular subtypes.…”

PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo

“…In contrast, patients whose tumors express a mesenchymal (MES) or classical (CL) signature typically exhibit a more rapid disease course, coupled with therapeutic resistance. 24,25 To further explore the clinical significance of F2R in gliomas, we correlated its expression with GBM subtype, as well as with common copy number variants and mutations identified in The Cancer Genomic Atlas (TCGA). F2R was enriched across GBM subtypes relative to normal GPCs, but most prominently so in GBMs of the CL subtype ( P < 0.01) (Figure 2a).…”

Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A as a Diagnostic and Prognostic Biomarker in Gliomas

“…A study with 941 malignant glioma samples found that the PN and Neural, and Classical and Mes subtypes frequently occurred in LGGs and HGGs, respectively (23). On the other hand, survival analyses demonstrated that the Mes subtype gliomas behaved a poor survival outcome and conversely the PN subtype gliomas displayed a better prognosis (23). Some previous studies found that IDH mutation was associated with 1p/19q codeletion (24), and glioma patients with IDH mutation had a longer median overall survival time than samples with IDH wildtype (25).…”